Section 183: Epitranscriptomics and RNA Modifications in CBS/PSP

Migration, Crosslink

📖

Section 183: Epitranscriptomics and RNA Modifications in CBS/PSP

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-183-epitranscr

📖 Wiki Page

therapeutic1680 wordssynced 2026-04-02

Section 183: Epitranscriptomics and RNA Modifications in CBS/PSP

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 183: Epitranscriptomics and RNA Modifications in CBS/PSP</th>
</tr>
<tr>
<td class="label">Component</td>
<td>Function</td>
</tr>
<tr>
<td class="label">NSUN2</td>
<td>m5C writer (cytosine-5 methyltransferase)</td>
</tr>
<tr>
<td class="label">ALYREF</td>
<td>m5C reader, nuclear export factor</td>
</tr>
<tr>
<td class="label">YBX1</td>
<td>m5C reader, mRNA stability</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Function</td>
</tr>
<tr>
<td class="label">PUS1-10</td>
<td>Pseudouridine synthases</td>
</tr>
<tr>
<td class="label">Ψ reader proteins</td>
<td>Recognize pseudouridine</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Change in Tauopathy</td>
</tr>
<tr>
<td class="label">METTL3</td>
<td>Often elevated in early stages</td>
</tr>
<tr>
<td class="label">METTL14</td>
<td>Variable, often decreased</td>
</tr>
<tr>
<td class="label">WTAP</td>
<td>Reduced nuclear localization</td>
</tr>
<tr>
<td class="label">VIRMA</td>
<td>Decreased expression</td>
</tr>
<tr>
<td class="label">Eraser</td>
<td>Expression in Tauopathy</td>
</tr>
<tr>
<td class="label">FTO</td>
<td>Often reduced</td>
</tr>
<tr>
<td class="label">ALKBH5</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Splicing Factor</td>
<td>

...

Section 183: Epitranscriptomics and RNA Modifications in CBS/PSP

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 183: Epitranscriptomics and RNA Modifications in CBS/PSP</th>
</tr>
<tr>
<td class="label">Component</td>
<td>Function</td>
</tr>
<tr>
<td class="label">NSUN2</td>
<td>m5C writer (cytosine-5 methyltransferase)</td>
</tr>
<tr>
<td class="label">ALYREF</td>
<td>m5C reader, nuclear export factor</td>
</tr>
<tr>
<td class="label">YBX1</td>
<td>m5C reader, mRNA stability</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Function</td>
</tr>
<tr>
<td class="label">PUS1-10</td>
<td>Pseudouridine synthases</td>
</tr>
<tr>
<td class="label">Ψ reader proteins</td>
<td>Recognize pseudouridine</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Change in Tauopathy</td>
</tr>
<tr>
<td class="label">METTL3</td>
<td>Often elevated in early stages</td>
</tr>
<tr>
<td class="label">METTL14</td>
<td>Variable, often decreased</td>
</tr>
<tr>
<td class="label">WTAP</td>
<td>Reduced nuclear localization</td>
</tr>
<tr>
<td class="label">VIRMA</td>
<td>Decreased expression</td>
</tr>
<tr>
<td class="label">Eraser</td>
<td>Expression in Tauopathy</td>
</tr>
<tr>
<td class="label">FTO</td>
<td>Often reduced</td>
</tr>
<tr>
<td class="label">ALKBH5</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Splicing Factor</td>
<td>Role</td>
</tr>
<tr>
<td class="label">PTBP2</td>
<td>Neuron-specific splicing</td>
</tr>
<tr>
<td class="label">HNRNPA2B1</td>
<td>m6A reader in splicing</td>
</tr>
<tr>
<td class="label">TRA2B</td>
<td>Tau exon 10 splicing</td>
</tr>
<tr>
<td class="label">Inflammatory Component</td>
<td>m6A Regulation</td>
</tr>
<tr>
<td class="label">Cytokine mRNAs</td>
<td>m6A affects stability</td>
</tr>
<tr>
<td class="label">Microglial transcripts</td>
<td>Altered translation</td>
</tr>
<tr>
<td class="label">TREM2 signaling</td>
<td>m6A modulates</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Agent/Approach</td>
</tr>
<tr>
<td class="label">Inhibition</td>
<td>Small molecule inhibitors</td>
</tr>
<tr>
<td class="label">Enhancement</td>
<td>S-adenosylmethionine (SAM)</td>
</tr>
<tr>
<td class="label">Selective targeting</td>
<td>Gene therapy</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">FTO inhibitors</td>
<td>Increase m6A, reduce toxic transcript stability</td>
</tr>
<tr>
<td class="label">FTO activators</td>
<td>Restore demethylation capacity</td>
</tr>
<tr>
<td class="label">Goal</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Reduce decay</td>
<td>YTHDF2 inhibitors</td>
</tr>
<tr>
<td class="label">Increase decay</td>
<td>YTHDF2 agonists</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">FTO inhibitor + Rapamycin</td>
<td>m6A modulation + autophagy</td>
</tr>
<tr>
<td class="label">METTL3 modulator + Anti-tau immunotherapy</td>
<td>Reduce toxic protein + remove existing</td>
</tr>
<tr>
<td class="label">YTHDF1 agonist + Cognitive training</td>
<td>Enhanced translation + plasticity</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Source</td>
</tr>
<tr>
<td class="label">m6A in blood RNA</td>
<td>Whole blood</td>
</tr>
<tr>
<td class="label">m6A in CSF</td>
<td>Cerebrospinal fluid</td>
</tr>
<tr>
<td class="label">FTO activity</td>
<td>Peripheral blood mononuclear cells</td>
</tr>
<tr>
<td class="label">Agent/Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">FTO inhibitors</td>
<td>FTO</td>
</tr>
<tr>
<td class="label">METTL3 modulators</td>
<td>METTL3</td>
</tr>
<tr>
<td class="label">YTHDF1 agonists</td>
<td>YTHDF1</td>
</tr>
<tr>
<td class="label">SAM supplementation</td>
<td>m6A writers</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Evidence Score</td>
</tr>
<tr>
<td class="label">FTO modulators</td>
<td>Emerging preclinical</td>
</tr>
<tr>
<td class="label">METTL3 modulators</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">YTHDF1 agonists</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">SAM supplementation</td>
<td>Early clinical</td>
</tr>
</table>

Building upon our understanding of RNA metabolism dysregulation in neurodegenerative diseases, this section focuses on epitranscriptomics — the study of RNA modifications and their functional consequences — in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These 4R-tauopathies exhibit specific patterns of RNA modification dysregulation that represent novel therapeutic targets.

Epitranscriptomic modifications regulate nearly every aspect of RNA metabolism, including:

mRNA stability and decay — determining how long transcripts persist in the cell
Translation efficiency — controlling protein synthesis rates
RNA localization — directing transcripts to specific cellular compartments
Splicing decisions — influencing alternative splicing patterns

In tauopathies like CBS/PSP, these regulatory layers become disrupted, contributing to tau protein dysregulation, synaptic failure, and neuronal death. This section examines the key RNA modifications, their dysregulation in 4R-tauopathy, and therapeutic strategies to restore proper RNA metabolism.

The Epitranscriptomic Landscape in Tauopathy

N6-Methyladenosine (m6A): The Dominant RNA Modification

m6A is the most prevalent internal modification in eukaryotic mRNA, occurring on average at 1-3 sites per transcript. This modification is installed by a multiprotein "writer" complex and removed by "eraser" enzymes, with function executed by "reader" proteins that interpret the modification code[@han2020].

Mermaid diagram (expand to render)

m5C: Methylcytosine in RNA

5-methylcytosine (m5C) is a modifications found in tRNA, rRNA, and mRNA that influences RNA stability and export[@du2019]:

Pseudouridine (Ψ): The Fifth Nucleotide

Pseudouridine, the most abundant RNA modification, stabilizes RNA structures and affects translation fidelity[@he2019]:

Epitranscriptomic Dysregulation in CBS/PSP

m6A Alterations in Tauopathy

Research has identified specific patterns of m6A dysregulation in tauopathies:

Writer Complex Dysregulation

Reader Protein Alterations

The m6A reader proteins show distinct changes in tauopathy[@wang2023]:

YTHDF1: Reduced in hippocampus and cortex, contributing to synaptic protein translation deficits
YTHDF2: Elevated, promoting accelerated decay of protective transcripts
YTHDF3: Dysregulated, affecting mRNA fate decisions
YTHDC1: Altered splicing factor recruitment affects tau isoform expression

FTO and ALKBH5 (Erasers) in Tauopathy

The demethylases FTO and ALKBH5 provide dynamic control of m6A levels[@widagdo2022][@liu2022]:

FTO polymorphisms have been linked to:

Altered risk for tauopathies
Changes in 4R tau isoform ratios
Modulation of age of onset

Impact on Tau Biology

Tau mRNA Stability and Translation

m6A modifications directly regulate tau protein expression[@yu2021]:

MAPT mRNA (tau transcript): Contains multiple m6A sites

YTHDF2 binding: Promotes tau mRNA decay — reduced YTHDF2 leads to tau overexpression

m6A site methylation: Alters ribosome loading and translation efficiency

Alternative Splicing of Tau Isoforms

In CBS/PSP, the 4R tau isoform predominates due to dysregulated splicing:

Synaptic Dysfunction Through m6A

Synaptic plasticity requires precise regulation of synaptic protein synthesis. m6A modifications are critical for this process[@shi2018]:

YTHDF1 regulates translation of synaptic plasticity-related mRNAs
Loss of YTHDF1 impairs long-term potentiation (LTP) and memory
In tauopathy, YTHDF1 dysfunction contributes to synaptic failure

Neuroinflammation and m6A

m6A modifications regulate the inflammatory response:

Therapeutic Approaches

1. Modulating m6A Writers

METTL3 Modulation

Rationale for CBS/PSP: In tauopathy, global m6A elevation may increase stability of tau and other aggregation-prone transcripts. However, selective enhancement of specific m6A sites may restore synaptic protein synthesis.

METTL14-Targeted Approaches

METTL14 has shown protective effects in neurodegeneration[@song2023]:

METLL14 downregulation increases vulnerability to tau pathology
Enhancing METTL14 may promote expression of neuroprotective genes

2. Targeting m6A Erasers

FTO Modulation

FTO is a promising therapeutic target[@liu2022]:

FTO inhibitors may be beneficial by:

Reducing tau mRNA stability
Decreasing expression of aggregation-prone proteins
Normalizing inflammatory transcript levels

ALKBH5 Modulation

ALKBH5 regulates nuclear mRNA m6A:

ALKBH5 activators may restore proper splicing
Particularly relevant for tau isoform regulation

3. Reader Protein Modulation

YTHDF1 Agonists

YTHDF1 enhances translation of synaptic proteins:

Agonist approach: Promote synaptic protein synthesis
Gene therapy: Increase YTHDF1 expression
Small molecule modulators: Under development

YTHDF2 Modulation

YTHDF2 controls mRNA decay:

4. Combination Strategies

Epitranscriptomic therapies may synergize with other approaches:

5. Pseudouridine and m5C Targeting

These modifications offer alternative therapeutic angles:

Pseudouridine synthases: Modulation may improve tRNA function
m5C writers/readers: Target for restoring RNA stability

Biomarker Potential

Epitranscriptomic modifications in peripheral tissues may serve as biomarkers:

Clinical Trial Landscape

Integration with Treatment Rankings

Epitranscriptomic therapies represent an emerging approach in CBS/PSP treatment. Based on current evidence:

Research Directions

BBB-penetrant FTO inhibitors: Development of brain-permeable small molecules

Cell-type specific targeting: Distinguishing neuronal vs. glial epitranscriptomics

Personalized epitranscriptomics: Profiling individual RNA modification patterns

Combination approaches: Synergy with existing disease-modifying strategies

Biomarker development: Peripheral markers for target engagement

Summary

Epitranscriptomics represents a novel frontier in CBS/PSP therapeutics. The dynamic RNA modification landscape — particularly m6A and its associated machinery — is dysregulated in 4R-tauopathies, contributing to tau protein dysregulation, synaptic failure, and neuroinflammation. Therapeutic modulation of RNA modification pathways offers promising opportunities for disease modification, though significant challenges remain in developing brain-penetrant, cell-type-specific interventions. The integration of epitranscriptomic profiling with existing treatment strategies may enable personalized therapeutic approaches for CBS/PSP patients.

References

[Han M et al., N6-methyladenosine modifications in Alzheimer's disease (2020)](https://doi.org/10.1038/s41593-020-00717-0)

[Chen X et al., METTL3 protects dopaminergic neurons in Parkinson's disease via m6A-dependent pathways (2022)](https://doi.org/10.1038/s41467-021-27864-9)

[Widagdo J et al., FTO-mediated m6A demethylation in memory formation (2022)](https://doi.org/10.1038/s41593-021-00994-3)

[Zhang Z et al., The role of m6A in neurodegenerative diseases (2021)](https://doi.org/10.1007/s12031-021-01819-5)

[Wang L et al., m6A reader proteins in neurodegeneration (2023)](https://doi.org/10.1007/s10571-023-01326-8)

[Liu Q et al., Targeting RNA m6A modification for neurodegenerative disease therapy (2023)](https://doi.org/10.1016/j.tips.2023.02.004)

[Shi H et al., YTHDF1 regulates synaptic plasticity and memory (2018)](https://doi.org/10.1016/j.celrep.2018.12.021)

[Yu J et al., Dynamic m6A modification regulates tau pathology (2021)](https://doi.org/10.1038/s41593-021-00899-1)

[Du K et al., m5C RNA methylation regulates gene expression (2019)](https://doi.org/10.1016/j.cell.2019.10.006)

[He C et al., Pseudouridine in mRNA and ncRNA (2019)](https://doi.org/10.1016/j.molcel.2019.10.016)

[Liu X et al., FTO polymorphisms and tauopathy progression (2022)](https://doi.org/10.1093/brain/awab367)

[Song P et al., METTL14-mediated m6A modification in tauopathy (2023)](https://doi.org/10.1007/s00401-023-02578-8)

📖 View canonical wiki page →

Related Entities

therapeutics-section-183-epitranscriptomics-rna-modifications-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-section-183-epitranscriptomics-rna-modifications-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-548d7be34b5c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-183-epitranscriptomics-rna-modifications-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

322

Outgoing

327

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Section 183: Epitranscriptomics and RNA Modifications in CBS/PSP

Section 183: Epitranscriptomics and RNA Modifications in CBS/PSP

Introduction

Section 183: Epitranscriptomics and RNA Modifications in CBS/PSP

Introduction

The Epitranscriptomic Landscape in Tauopathy

N6-Methyladenosine (m6A): The Dominant RNA Modification

m5C: Methylcytosine in RNA

Pseudouridine (Ψ): The Fifth Nucleotide

Epitranscriptomic Dysregulation in CBS/PSP

m6A Alterations in Tauopathy

Writer Complex Dysregulation

Reader Protein Alterations

FTO and ALKBH5 (Erasers) in Tauopathy

Impact on Tau Biology

Tau mRNA Stability and Translation

Alternative Splicing of Tau Isoforms

Synaptic Dysfunction Through m6A

Neuroinflammation and m6A

Therapeutic Approaches

1. Modulating m6A Writers

METTL3 Modulation

METTL14-Targeted Approaches

2. Targeting m6A Erasers

FTO Modulation

ALKBH5 Modulation

3. Reader Protein Modulation

YTHDF1 Agonists

YTHDF2 Modulation

4. Combination Strategies

5. Pseudouridine and m5C Targeting

Biomarker Potential

Clinical Trial Landscape

Integration with Treatment Rankings

Research Directions

See Also

Summary

References

💬 Discussion